Important role of indels in somatic mutations of human cancer genes.
BACKGROUND
Cancer is clonal proliferation that arises owing to mutations in a subset of genes that confer growth advantage. More and more cancer related genes are found to have accumulated somatic mutations. However, little has been reported about mutational patterns of insertions/deletions (indels) in these genes.


RESULTS
We analyzed indels' abundance and distribution, the relative ratio between indels and somatic base substitutions and the association between those two forms of mutations in a large number of somatic mutations in the Catalogue of Somatic Mutations in Cancer database. We found a strong correlation between indels and base substitutions in cancer-related genes and showed that they tend to concentrate at the same locus in the coding sequences within the same samples. More importantly, a much higher proportion of indels were observed in somatic mutations, as compared to meiotic ones. Furthermore, our analysis demonstrated a great diversity of indels at some loci of cancer-related genes. Particularly in the genes with abundant mutations, the proportion of 3n indels in oncogenes is 7.9 times higher than that in tumor suppressor genes.


CONCLUSIONS
There are three distinct patterns of indel distribution in somatic mutations: high proportion, great abundance and non-random distribution. Because of the great influence of indels on gene function (e.g., the effect of frameshift mutation), these patterns indicate that indels are frequently under positive selection and can often be the 'driver mutations' in oncogenesis. Such driver forces can better explain why much less frameshift mutations are in oncogenes while much more in tumor suppressor genes, because of their different function in oncogenesis. These findings contribute to our understanding of mutational patterns and the relationship between indels and cancer.
Yang
Haiwang
H
State Key Laboratory of Pharmaceutical Biotechnology, Department of Biology, Nanjing University, Nanjing 210093, China.
Zhong
Yan
Y
Peng
Cheng
C
Chen
Jian-Qun
JQ
Tian
Dacheng
D
D022762:CCAAT-Enhancer-Binding Proteins / Q000235:genetics; D016208:Databases, Factual; D052138:Genes, Neoplasm; D006801:Humans; D054643:INDEL Mutation; D009369:Neoplasms / Q000235:genetics*; D009857:Oncogenes; D025521:Tumor Suppressor Proteins / Q000235:genetics
D022762:CCAAT-Enhancer-Binding Proteins; C515848:CEBPA protein, human; D025521:Tumor Suppressor Proteins
Hum Genet. 2005 May;116(6):433-44
15726414
Gene. 2003 Jul 17;312:257-61
12909362
Nature. 2010 Jan 14;463(7278):191-6
20016485
Nat Med. 2004 Aug;10(8):789-99
15286780
Nucleic Acids Res. 2010 Jan;38(Database issue):D652-7
19906727
Hum Mutat. 2003 Jan;21(1):12-27
12497628
Br J Cancer. 2004 Jul 19;91(2):355-8
15188009
Nat Rev Genet. 2006 Jan;7(1):21-33
16369569
Science. 1976 Oct 1;194(4260):23-8
959840
Mov Disord. 2004 Oct;19(10):1146-57
15390068
Cancer Res. 2004 Aug 1;64(15):5518-24
15289363
Genetica. 2002 May;115(1):81-91
12188050
Curr Protoc Hum Genet. 2008 Apr;Chapter 10:Unit 10.11
18428421
Nat Rev Mol Cell Biol. 2010 Mar;11(3):196-207
20177395
Nature. 2007 Mar 8;446(7132):153-8
17344846
Nature. 2008 Sep 4;455(7209):105-8
18641631
Hum Mutat. 2000;16(2):109-22
10923032
Nat Rev Cancer. 2004 Mar;4(3):177-83
14993899
Mol Biol Evol. 2009 Oct;26(10):2353-61
19587128
Nature. 2001 May 17;411(6835):336-41
11357140
Trends Genet. 2002 Nov;18(11):544-7
12414177
Bioessays. 2009 Sep;31(9):912-20
19644920
Cancer Res. 2009 Oct 15;69(20):8094-101
19789351
Nat Rev Cancer. 2005 Feb;5(2):113-25
15660110
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11642-6
16868089
Nature. 2009 Apr 9;458(7239):719-24
19360079
Nature. 2009 Aug 20;460(7258):1011-5
19587683
Science. 1996 May 3;272(5262):725-8
8614834
BMC Genomics. 2007 Jun 20;8:185
17584915
Nature. 2009 Jan 1;457(7225):36-7
19122629
Genome Res. 2003 Jan;13(1):13-26
12529302
Mol Biol Evol. 2009 Jul;26(7):1523-31
19329651
FASEB J. 2008 Aug;22(8):2605-22
18434431